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the ELISA-2 positives were matched with RIBA HCV 2.0 SIA-positive patients, a subgroup were randomly selected and evaluated by RIBA HCV 3.0 SIA. Positive sera detected through ELISA-3 were analysed by RIBA HCV 2.0 and 3.0 SIA tests by RT-PCR. Serum AST and ALT activities, determined by spectrophotometry every 3 months, were retrospectively evaluated after the onset of HD. A follow-up sample from each patient was obtained 1 month later. It was assumed that all 190 patients were tested semiannually for anti-HCV whereas confirmatory assays on these patients were done once a year.
Analysis of effectiveness
The analysis of the study was based on intention to treat. The main health outcomes were improvement in the quality of care and improvement of both sensitivity and specificity of the HCV tests.
Effectiveness results
The prevalence of anti-HCV antibodies was 25% (48/190) when tested by third generation tests compared to 28% (53/190) in the second-generation testing group.56% (9/16) of patients showing uncertain findings by secondgeneration tests gave unequivocal results by third-generation assays. The median duration of HD treatment was 59 and 36 months, for anti-HCV positive and negative patients, respectively. Median duration of HD treatment and raised aminotransferase levels were positively associated (P=0.004 and P=0.012, respectively) with anti-HCV detected by third-generation assays. Among the 190 HD patients, 25 (13%) showed raised AST and ALT concentrations; 16 of them (64%) exhibited multiple peaks.13 out of the 25 (52%) were anti-HCV positive and, of these, 9 were positive by second-generation tests, and 4 gave unclear results.
Clinical conclusions
Third generation screening and confirmatory assays seemed extremely useful in the serologic survey for control of hepatitis C in haemodialysis centres.
Modelling
None.
Measure of benefits used in the economic analysis
The main health outcome was improvement in the quality of care and improvement of both sensitivity and specificity of the tests.
